A Multiomics-Informed HLA Signature Predicts Immunotherapy Response

Skip Nav Destination

June 12, 2024

Major Finding: A neoantigen-favoring HLA signature predicts immunotherapy response in clear-cell renal cell carcinoma.

Concept: A cross-omics machine learning model resolved a signature reflecting neoantigen-specific HLA alleles.

Impact: Combination treatment with immunotherapy and a CD40 agonist may be synergistic in renal cell carcinoma.

DOI:https://doi.org/10.1158/2159-8290.CD-RW2024-083

Article Type: Research Watch

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

A Multiomics-Informed HLA Signature Predicts Immunotherapy Response Available to Purchase